Moraga, CA, United States of America

Alan M Ezrin

USPTO Granted Patents = 18 

Average Co-Inventor Count = 4.4

ph-index = 14

Forward Citations = 1,147(Granted Patents)


Company Filing History:


Years Active: 1998-2007

Loading Chart...
18 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Alan M Ezrin - Pioneering Endogenous Therapeutic Compound Protection

Introduction:

Alan M Ezrin, a renowned inventor based in Moraga, CA, has made significant contributions to the field of biotechnology with a remarkable portfolio of 18 patents. A standout among his inventions is the groundbreaking method for protecting endogenous therapeutic peptides from peptidase activity through conjugation to blood components.

Latest Patents:

Alan M Ezrin's latest patents revolve around safeguarding therapeutic peptides using innovative conjugation techniques. In his recent work, he devised a method to enhance the stability and therapeutic efficacy of secretin derivatives by forming stable covalent bonds with blood components. This approach ensures a prolonged maintenance of therapeutic activity compared to unconjugated peptides, thereby revolutionizing peptide-based treatments.

Career Highlights:

Throughout his career, Alan M Ezrin has demonstrated a strong commitment to advancing biotechnological solutions. He has held pivotal roles at companies like Conjuchem, Inc. and Conjuchem Biotechnologies Inc., where he played an instrumental part in driving research and development initiatives focused on novel drug delivery systems and therapeutic peptides. His expertise in peptide protection mechanisms has garnered recognition within the scientific community.

Collaborations:

Alan M Ezrin has collaborated closely with esteemed professionals in the field, including distinguished coworkers such as Dominique P Bridon and Darren L Holmes. Together, they have synergized their expertise to propel the development of innovative bioconjugation technologies aimed at enhancing the bioavailability and efficacy of therapeutic peptides. Such collaborative efforts have led to the successful implementation of cutting-edge methodologies in the biopharmaceutical landscape.

Conclusion:

In conclusion, Alan M Ezrin stands as a trailblazer in the realm of biotechnology, particularly in the domain of endogenous therapeutic compound protection. His inventive approach to peptide stabilization through conjugation to blood components has paved the way for novel therapeutic interventions with enhanced stability and efficacy. With a track record of pioneering patents and collaborative successes, Alan M Ezrin continues to shape the future of biopharmaceutical innovation with his groundbreaking contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…